Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Raltegravir resistance in the cerebrospinal fluid.

Mora-Peris B, Mackie NE, Suan D, Cooper DA, Brew BJ, Winston A.

Infection. 2013 Jun;41(3):731-4. doi: 10.1007/s15010-013-0409-z. Epub 2013 Feb 3.

PMID:
23378293
2.

Emergence of raltegravir-resistant HIV-1 in the central nervous system.

Watanabe K, Honda M, Watanabe T, Tsukada K, Teruya K, Kikuchi Y, Oka S, Gatanaga H.

Int J STD AIDS. 2010 Dec;21(12):840-1. doi: 10.1258/ijsa.2009.009283.

PMID:
21297097
3.

HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape.

Bingham R, Ahmed N, Rangi P, Johnson M, Tyrer M, Green J.

Int J STD AIDS. 2011 Oct;22(10):608-9. doi: 10.1258/ijsa.2011.010507.

PMID:
21998185
4.

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.

Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M.

Clin Microbiol Infect. 2011 Jun;17(6):928-34. doi: 10.1111/j.1469-0691.2010.03375.x. Epub 2010 Nov 5.

5.

Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Günthard HF, Good B, Smith DM, Wolinsky SM, Furtado M, Marquie-Beck J, Durelle J, Grant I, Richman DD, Marcotte T, McCutchan JA, Ellis RJ, Wong JK.

J Virol. 2005 Feb;79(3):1772-88.

6.

[HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART].

Sekiya H, Kawamoto M, Togo M, Yoshimura H, Imai Y, Kohara N.

Rinsho Shinkeigaku. 2014;54(9):721-5. Japanese.

PMID:
25283826
7.

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.

Nguyen TT, Rato S, Molina JM, Clavel F, Delaugerre C, Mammano F.

J Antimicrob Chemother. 2015 Mar;70(3):731-8. doi: 10.1093/jac/dku424. Epub 2014 Oct 21.

PMID:
25336162
8.

Foscarnet activity on human immunodeficiency virus type 1 in the central nervous system.

Delforge ML, Farber CM, De Leener F, Caroyer JM, Liesnard C, Van Vooren JP.

Clin Infect Dis. 1999 Apr;28(4):931. No abstract available.

PMID:
10825078
9.

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2011 Dec;66(12):2827-30. doi: 10.1093/jac/dkr389. Epub 2011 Sep 19.

PMID:
21933786
11.

Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient.

Delaugerre C, Denis B, Peytavin G, Palmer P, Mourez T, Le Goff J, Molina JM, Simon F.

J Clin Microbiol. 2009 Nov;47(11):3763-4. doi: 10.1128/JCM.00206-09. Epub 2009 Sep 16.

12.

Raltegravir: the first HIV type 1 integrase inhibitor.

Hicks C, Gulick RM.

Clin Infect Dis. 2009 Apr 1;48(7):931-9. doi: 10.1086/597290. Review.

PMID:
19231980
13.

HIV encephalitis related to the development of a discordant resistant virus in CNS.

Pérez-Rodríguez MT, Sousa A, Martínez-Cueto P, Ocampo A.

Clin Microbiol Infect. 2015 Aug;21(8):e59-60. doi: 10.1016/j.cmi.2015.05.003. Epub 2015 May 14. No abstract available.

14.

Risk factors for raltegravir resistance development in clinical practice.

Malet I, Fourati S, Morand-Joubert L, Flandre P, Wirden M, Haim-Boukobza S, Sayon S, Pattery T, Simon A, Katlama C, Girard PM, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2012 Oct;67(10):2494-500. doi: 10.1093/jac/dks254. Epub 2012 Jul 4.

PMID:
22763565
15.

In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.

Souza Cavalcanti J, Minhoto Lança A, de Paula Ferreira JL, da Eira M, de Souza Dantas DS, de Macedo Brígido LF.

Antiviral Res. 2012 Jul;95(1):9-11. doi: 10.1016/j.antiviral.2012.04.007. Epub 2012 May 4.

16.

Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.

van Lelyveld SF, Nijhuis M, Baatz F, Wilting I, van den Bergh WM, Kurowski M, de Jong D, Hoepelman AI, Wensing AM.

Clin Infect Dis. 2010 Feb 1;50(3):387-90. doi: 10.1086/649874.

PMID:
20047481
17.

HIV-associated dementia.

Major EO, Rausch D, Marra C, Clifford D.

Science. 2000 Apr 21;288(5465):440-2. No abstract available.

PMID:
10798979
18.

Raltegravir and etravirine are active against HIV type 1 group O.

Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V.

AIDS Res Hum Retroviruses. 2009 Feb;25(2):225-7. doi: 10.1089/aid.2008.0222.

PMID:
19239363
19.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M; Antiretroviral Resistance Cohort Analysis Collaborative Group.

Clin Microbiol Infect. 2013 Oct;19(10):936-42. doi: 10.1111/1469-0691.12100. Epub 2013 Jan 4.

20.

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M.

J Antimicrob Chemother. 2013 Nov;68(11):2525-32. doi: 10.1093/jac/dkt220. Epub 2013 Jun 24.

PMID:
23798668

Supplemental Content

Support Center